WASHINGTON — The Food and Drug Administration granted accelerated approval Friday to AstraZeneca’s Etcamah for adults with advanced breast cancer, a move intended to expand access to new treatments to patients who need them. The approval permits Etcamah, also known as camizestrant, to be used with one of three CDK4/6 inhibitors — abemaciclib, palbociclib or …
Continue reading “FDA Grants Accelerated Approval to a New Breast Cancer Treatment”
The post FDA Grants Accelerated Approval to a New Breast Cancer Treatment appeared first on The Well News | Pragmatic, Governance, Fiscally Responsible, News & Analysis. Read More
